SimfliBIO Overview

  • Year Founded
  • 2022

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Seed

  • Investors
  • 3

SimfliBIO General Information

Description

Developer of the liquid biopsy technique intended to perform less invasive gene mutation detection. The company detects gene mutations based on ctDNA in blood content using probes that complementarily bind to mutation-causing DNA or RNA sequences, helping physicians diagnose cancer using bodily fluids.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 111, Building 22, College of Natural Sciences, 1 Gwanak-ro
  • Sillim-dong, Seoul National University, Gwanak-gu
  • Seoul, 08826
  • South Korea
Primary Industry
Biotechnology
Other Industries
Diagnostic Equipment
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 111, Building 22, College of Natural Sciences, 1 Gwanak-ro
  • Sillim-dong, Seoul National University, Gwanak-gu
  • Seoul, 08826
  • South Korea

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

SimfliBIO Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Seed Round 21-Jun-2025 Completed Startup
1. Accelerator/Incubator 04-Apr-2025 Completed Startup
To view SimfliBIO’s complete valuation and funding history, request access »

SimfliBIO Patents

  • 5

    Total Documents Applications and Grants

  • Total Patents Families

  • 2

    Granted

  • 3

    Pending

  • Expiring in next 12 mo

SimfliBIO Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4663770-A1 Method for detecting mutant nucleic acid Pending 08-Feb-2023
US-20260226529-A1 Method for detecting mutant nucleic acid Pending 08-Feb-2023
US-12668832-B2 Method for detecting polynucleotide using risc Active 01-Apr-2019
US-20220098649-A1 Method for detecting polynucleotide using risc Active 01-Apr-2019
US-20260265822-A1 Method for detecting polynucleotide using risc Pending 01-Apr-2019 C12Q1/6876
To view SimfliBIO’s complete patent history, request access »

SimfliBIO Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds
First Gate Venture Capital Minority
Korea Omega Investment Venture Capital Minority
WOW Partners Venture Capital Minority
To view SimfliBIO’s complete investors history, request access »

Ready to get started?

Request a free trial

SimfliBIO FAQs

  • When was SimfliBIO founded?

    SimfliBIO was founded in 2022.

  • Where is SimfliBIO headquartered?

    SimfliBIO is headquartered in Seoul, South Korea.

  • What industry is SimfliBIO in?

    SimfliBIO’s primary industry is Biotechnology.

  • Is SimfliBIO a private or public company?

    SimfliBIO is a Private company.

  • What is SimfliBIO’s current revenue?

    The current revenue for SimfliBIO is .

  • Who are SimfliBIO’s investors?

    First Gate, Korea Omega Investment, and WOW Partners have invested in SimfliBIO.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process